Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
rubber dildos.
Popular Articles

Aiming For Early Diagnosis For ADHD And Parkinson's Disease
Eye movement tests developed by Queen"s University researchers to aid in understanding childhood brain development and healthy aging may also help in the diagnosis of Attention Deficit Hyperactivity Disorder and detecting the early onset of Parkinson"s disease. The project has received close to $1 million in recent funding from the Canadian Institutes of Health Research (CIHR).
diet pills
Light-Treatment Device Developed To Improve Sleep Quality In The Elderly
Sleep disturbances increase as we age. Some studies report more than half of seniors 65 years of age or older suffer from chronic sleep disturbances. Researchers have long believed that the sleep disturbances common among the elderly often result from a disruption of the body"s circadian rhythms - biological cycles that repeat approximately every 24 hours.
News of the day
Celleron Therapeutics And Astrazeneca Announce Personalised Medicine Collaboration In Cancer For The Development Of AZ's Leading HDAC Inhibitor
Celleron Therapeutics Ltd, the Oxford UK based specialist in the development of individually targeted cancer medicines, has secured exclusive rights to AstraZeneca plc"s lead histone deacetylase (HDAC) inhibitor (AZD 9468), for global development in conjunction with its proprietary "CancerNav" predictive biomarker platform. "CancerNav" specifically identifies those tumours which are most likely to respond to an individual cancer drug, thereby enabling a highly focussed clinical development and commercialisation programme, based on a closely linked diagnostic and therapeutic "personalised medicine" approach.
Public Health

Prospect Therapeutics, Inc.'s GCS-100 Inhibited Blood Vessel Formation In A Variety Of Cancer Models

Joseph F. Finn, Jr., C.P.A. ("Finn"), announced today that there has been promising initial interest from pharma companies in the intellectual property of Prospect Therapeutics, Inc. ("Prospect"). In preclinical studies, GCS-100 inhibited blood vessel formation in a variety of cancer models. Development and growth of solid tumors requires new blood vessel growth, or angiogenesis, to deliver oxygen and nutrients to a tumor. Galectin-3 also plays an important role in stimulating angiogenesis in a variety of tissues. The intellectual property, regulatory dossier, fixed assets and clinical inventory will be sold at auction on Monday, June 29, 2009 at 12:00 noon. Persons interested in bidding must sign a Confidentiality Agreement ("CA") obtained from Finn"s Office - jffinnjr@earthlink.net or 781-237-8840. They will then receive a bid package. About Prospect Therapeutics, Inc. Prospect"s lead product candidate, GCS-100, is a carbohydrate molecule designed to inhibit the activity of Galectin-3, a protein found in high concentration in a broad range of human cancers and whose over-expression is associated with poor prognosis in cancer patients. Joseph F. Finn, Jr., C.P.A.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009